HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

[Cooperative phase II study of releasing tegafur (SF-SP) against advanced digestive cancers].

Abstract
A Phase II Study of single oral administration of SF-SP containing sustained-release granules of tegafur was conducted in 37 cases of advanced cancers by 9 institutions in the Hokkaido area. Two capsules each containing 200 or 250 mg of SF-SP were orally administered twice daily for a total of either 800 or 1000 mg per day. The results were as follows: Of the 24 evaluable cases PR was observed in 4 cases. (16.7%) The observed efficacy rate by cancer type was 23.5% for gastric cancer and toxicity was observed in 10 (27.8%) of 35 subject cases. These results thus indicate SF-SP to be therapeutically effective for treatment of gastric cancers, with mild toxicity.
AuthorsJ Ibayashi
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 11 Issue 7 Pg. 1414-9 (Jul 1984) ISSN: 0385-0684 [Print] JAPAN
PMID6430244 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Delayed-Action Preparations
  • Tegafur
  • Fluorouracil
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Colonic Neoplasms (drug therapy)
  • Delayed-Action Preparations
  • Digestive System Neoplasms (drug therapy)
  • Drug Evaluation
  • Esophageal Neoplasms (drug therapy)
  • Female
  • Fluorouracil (analogs & derivatives)
  • Humans
  • Male
  • Middle Aged
  • Pancreatic Neoplasms (drug therapy)
  • Stomach Neoplasms (drug therapy)
  • Tegafur (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: